Guggenheim Rates Guardant Health (GH) buy, $160 Price Target

Guggenheim maintains its buy rating and sets a $160 target for Guardant Health, a 6.65% upside from the current price.

By TradeTexts Research Desk · Published Jun 29, 2026, 10:00 AM EDT · Updated Jul 1, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Guardant Health, Inc. ($GH) "buy" with a $160 price target on June 29, 2026.

Since the rating, $GH is up 9.8% after 1 week, down 6.3% after 1 month and up 3.2% to date (from the $153.74 close on Jun 29, 2026).

GH Guardant Health, Inc.

$158.60 +55.89% year to date

Daily close · Oct 16, 2026

Key Points

On June 29, 2026, Guggenheim reiterated its buy rating on Guardant Health, Inc. (GH) with a price target of $160.
Guggenheim's $160 price target implies 6.65% upside from Guardant Health, Inc.'s ($GH) current $150.03 share price.
Shares of GH traded at $149.22 on Monday, with a market cap of approximately $19.79 billion and a 52-week high of $151.85.
Other analysts like Bernstein and Barclays also maintain a positive outlook, highlighting strong institutional interest in Guardant Health.

Get $GH trade alerts by text

We text you when insiders, Congress or big funds trade $GH. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures

Guggenheim reiterated its buy rating on Guardant Health, Inc. (NasdaqGS: GH) on June 29, 2026. The firm set a price target of $160 for the precision oncology company. Shares of Guardant Health traded at $149.22 on Monday.

Analysts Set New Price Targets

On June 29, 2026, Guggenheim maintained its buy rating on Guardant Health, Inc. with a $160 price target. Bernstein also reinstated a buy rating with a target of $175 on June 26, 2026. Barclays maintained its buy rating with a $150 target on June 24, 2026. Other firms like RBC Capital and Goldman Sachs also show strong buy ratings, with targets of $185 and $165, respectively.

Other Institutional Activity in Guardant Health

BLACKROCK, INC. grew its holdings by 236,045 shares, ending with 11,553,759 shares worth about $1.07 billion. PRICE T ROWE ASSOCIATES INC /MD/ increased its position by 1,387,611 shares, bringing its total to 7,023,689 shares valued at approximately $648.78 million. VANGUARD PORTFOLIO MANAGEMENT LLC and VANGUARD CAPITAL MANAGEMENT LLC both opened new positions, holding 5,837,992 and 5,624,180 shares, respectively. Meanwhile, INVESCO LTD. reduced its stake by 369,465 shares, now holding 4,946,469 shares valued at about $456.91 million.

Guardant Health, Inc. Stock Down 9.6%

Shares of NasdaqGS:GH traded near $149.22 on Monday. Guardant Health has a market cap of approximately $19.79 billion. The company's forward P/E ratio is not meaningful as it is not currently profitable, with a beta of 1.619. The stock's 52-week low is $40.35, and its 52-week high is $151.85. It also has a 50-day moving average of $111.18 and a 200-day moving average of $95.82.

12-month forecast

$GH price target

Guardant Health, Inc. daily closes and this analyst's $160 target. Not advice.

Insider Buying and Selling at Guardant Health, Inc.

On June 22, 2026, insiders Tariq Musa and Myrtle Potter planned sales of 1,951 and 1,556 shares, respectively, at an average price of $131.16. Roberto Mignone had several transactions, both buying and selling 264 shares, without a disclosed price, on June 21 and May 21, 2026.

About Guardant Health, Inc.

Guardant Health, Inc. is a healthcare company specializing in precision oncology. Based in Palo Alto, California, it provides blood and tissue tests, including the Guardant360 CDx and Guardant360 Liquid tests, which offer insights into tumor genetics. The company also offers the Guardant Reveal test for early cancer detection and the GuardantINFINITY test for comprehensive tumor profiling. Led by CEO Dr. Helmy Eltoukhy, the company employs about 2,490 people.

Bottom Line

Guardant Health continues to attract interest from analysts and institutional investors, with Guggenheim and others maintaining strong buy ratings. The company's stock performance and innovative cancer detection technologies make it a closely watched player in the healthcare sector. Investors should note that analyst ratings are forward-looking and subject to change.